BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

928 related articles for article (PubMed ID: 35154117)

  • 1. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer.
    Lu H; Wu J; Liang L; Wang X; Cai H
    Front Immunol; 2022; 13():803355. PubMed ID: 35154117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
    Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
    Front Oncol; 2023; 13():972558. PubMed ID: 37064115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
    Tan Z; Fu S; Zuo J; Wang J; Wang H
    Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
    Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
    Front Immunol; 2022; 13():916800. PubMed ID: 35860239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pyroptosis-related lncRNA signature predicts prognosis and immune microenvironment in head and neck squamous cell carcinoma.
    Zhu W; Ye Z; Chen L; Liang H; Cai Q
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108268. PubMed ID: 34688154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis Risk Model Based on Pyroptosis-Related lncRNAs for Bladder Cancer.
    Lu Z; Tang F; Li Z; Lai Y; Lu Z; Zhang J; Tang Z; Cai W; He Z
    Dis Markers; 2022; 2022():7931393. PubMed ID: 35154513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of five long noncoding RNAs signature and risk score for prognosis of bladder urothelial carcinoma.
    Zhang C; Li Z; Hu J; Qi F; Li X; Luo J
    J Cell Biochem; 2020 Jan; 121(1):856-866. PubMed ID: 31373406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
    Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
    Front Immunol; 2021; 12():791924. PubMed ID: 34975891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer.
    Feng ZH; Liang YP; Cen JJ; Yao HH; Lin HS; Li JY; Liang H; Wang Z; Deng Q; Cao JZ; Huang Y; Wei JH; Luo JH; Chen W; Chen ZH
    J Transl Med; 2022 Oct; 20(1):492. PubMed ID: 36309694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of the pyroptosis-related long noncoding rna signature to predict the prognosis of patients with bladder cancer.
    Wu Z; Zeng J; Wu M; Liang Q; Li B; Hou G; Lin Z; Xu W
    Medicine (Baltimore); 2023 Feb; 102(8):e33075. PubMed ID: 36827075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of pyroptosis-related lncRNAs prediction model for bladder cancer.
    Lia T; Shao Y; Regmi P; Li X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 35024796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration.
    Wang Z; Cao L; Zhou S; Lyu J; Gao Y; Yang R
    Front Immunol; 2022; 13():854785. PubMed ID: 35392086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a pyroptosis-associated long non-coding RNA signature for predicting the immune status and prognosis in skin cutaneous melanoma.
    Wu L; Liu G; He YW; Chen R; Wu ZY
    Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5597-5609. PubMed ID: 34604952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence.
    Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M
    Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
    Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H
    Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide Exploration of a Pyroptosis-Related Long Non-Coding RNA Signature Associated With the Prognosis and Immune Response in Patients With Bladder Cancer.
    Gao X; Cai J
    Front Genet; 2022; 13():865204. PubMed ID: 35571063
    [No Abstract]   [Full Text] [Related]  

  • 20. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
    Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
    World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.